It's quick, safe, and relatively painless, and if interventional radiologists want to own it, they'd better step up quickly: Endovenous laser treatment of varicose veins is poised to take off, according to Cornell University researchers. A two-year follow-up of 97 treated limbs showed a 6% recurrence rate, compared with 10% or higher recurrence reported for surgery, radio-frequency ablation, and transcatheter sclerotherapy.
It's quick, safe, and relatively painless, and if interventional radiologists want to own it, they'd better step up quickly: Endovenous laser treatment of varicose veins is poised to take off, according to Cornell University researchers. A two-year follow-up of 97 treated limbs showed a 6% recurrence rate, compared with 10% or higher recurrence reported for surgery, radio-frequency ablation, and transcatheter sclerotherapy.
The study was presented in January at the 15th Annual International Symposium on Endovascular Therapy.
Approved by the FDA in January 2002, laser treatment can be performed in an outpatient setting and is less expensive than surgery, with little reported patient discomfort.
"Most of the people qualified to perform this procedure should be interventional radiologists, but over the next couple of years there'll be thousands of physicians doing it, including vascular and general surgeons and even dermatologists," said Dr. Robert Min, coauthor and director of Cornell's new vascular center.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.